Showing results (911-920 of 4,873) with videos related to

Sort By:
Pageof 488
Urologic Oncology|July 23, 2019
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancerJason Zhu, Matthew Tucker, Daniele Marin, et al.
Urologic Oncology|July 23, 2019
Diet and lifestyle considerations for patients with prostate cancerKyle B Zuniga, June M Chan, Charles J Ryan, et al.
Urologic Oncology|February 5, 2017
Alcohol consumption and the risk of renal cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). Wozniak MB, Brennan P, Brenner DR, Overvad K, Olsen A, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Fagherazzi G, Katzke V, Kühn T, Boeing H, Bergmann MM, Steffen A, Naska A, Trichopoulou A, Trichopoulos D, Saieva C, Grioni S, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Hjartåker A, Weiderpass E, Arriola L, Molina-Montes E, Duell EJ, Santiuste C, Alonso de la Torre R, Barricarte Gurrea A, Stocks T, Johansson M, Ljungberg B, Wareham N, Khaw KT, Travis RC, Cross AJ, Murphy N, Riboli E, Scelo G.Int J Cancer. 2015 Oct 15;137(8):1953-66. [Epub 2015 Apr 28]. doi: 10.1002/ijc.29559Raman Jay, P Brennan, Brenner, et al.
Urologic Oncology|February 21, 2017
Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7Eggener Scott, J Adolfsson, M Aly, et al.
Urologic Oncology|February 1, 2017
Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomyDonghyun Lee, Sangjun Yoo, Dalsan You, et al.
Urologic Oncology|July 13, 2019
The estimated prevalence of missed positive lymph nodes based on extent of lymphadenectomy at radical prostatectomyNicholas H Chakiryan, Ann Martinez Acevedo, Michael J Conlin, et al.
Urologic Oncology|July 13, 2019
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysisMehdi Kardoust Parizi, Mohammad Abufaraj, Harun Fajkovic, et al.
Urologic Oncology|July 13, 2019
How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladderCarlotta Palumbo, Francesco A Mistretta, Sophie Knipper, et al.
Urologic Oncology|March 5, 2019
Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate compositionManuel Scimeca, Rita Bonfiglio, Nicoletta Urbano, et al.
Urologic Oncology|January 22, 2017
TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinomaZachary A Glaser, Harold D Love, Shunhua Guo, et al.
Pageof 488